Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
THURSDAY, NOVEMBER 15, 2012
From the HCVAdvocat
Interferon-free hepatitis C treatment safe, proves effective in up to 63% of patients with cirrhosis
The first major data on interferon-free hepatitis C treatment in people with cirrhosis shows that treatment can be safe, and proved effective in up to 63% of patients, according to results from the SOUND-C2 study presented this week at the 63rd meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
Despite their higher risk of progression to decompensated cirrhosis and liver cancer, most earlier-stage research studies of new hepatitis C drugs exclude people with more severe liver damage on the grounds of safety and the unpredictable processing of drugs by a more damaged liver. Moreover, because response rates tend to be poorer in this population, which would make the drug appear to perform poorly in comparison with competitor products, companies are unlikely to risk harming early perceptions of products by recruiting cirrhotic patients into general phase II trials.
From the HCVAdvocat
Interferon-free hepatitis C treatment safe, proves effective in up to 63% of patients with cirrhosis
The first major data on interferon-free hepatitis C treatment in people with cirrhosis shows that treatment can be safe, and proved effective in up to 63% of patients, according to results from the SOUND-C2 study presented this week at the 63rd meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
Despite their higher risk of progression to decompensated cirrhosis and liver cancer, most earlier-stage research studies of new hepatitis C drugs exclude people with more severe liver damage on the grounds of safety and the unpredictable processing of drugs by a more damaged liver. Moreover, because response rates tend to be poorer in this population, which would make the drug appear to perform poorly in comparison with competitor products, companies are unlikely to risk harming early perceptions of products by recruiting cirrhotic patients into general phase II trials.
Weird...
Not going to let it get me down :)
it's true!
just throwing it out there. I'm most certain 'big pharma' $$$$ thinks not.
see:
http://hcvadvocate.blogspot.ca/2012/11/interferon-free-hepatitis-c-treatment.html
If you Google to other sites that same link is dead .. weird
I HOPE.